- Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions - http://eyedocnews.com -

Ocriplasmin Approved by FDA to Treat Vitreomacular Adhesion

Posted By Dr. Ari Weitzner On July 31, 2012 @ 5:39 am In Industry News,Retina | Comments Disabled

We’ve previously monitored developments with respect to ThromboGenics ocriplasmin for treatment of vitreomacular adhesion [1].

Last Thursday, an FDA panel recommended ThromboGenics NV’s ocriplasmin as a treatment for vitreomacular adhesion. The panel concluded that the injectable drug, marketed under the brand name Jetrea, helped enough people in clinical trials to warrant a favorable review, despite evidence of adverse effects including eye pain, swelling and blurred vision.

Click here [2] for the full release (PDF).

Article printed from Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions: http://eyedocnews.com

URL to article: http://eyedocnews.com/006831-ocriplasmin-approved-by-fda-to-treat-vitreomacular-adhesion/

URLs in this post:

[1] ocriplasmin for treatment of vitreomacular adhesion: http://eyedocnews.com/005927-thrombogenics-announces-new-phase-iii-ocriplasmin-data-presented-at-the-2011-annual-meeting-of-the-american-society-of-retina-specialists-asrs/

[2] Click here: http://thrombogenics.com/wp-content/uploads/2011/03/12_THR_22_FDA-AdCom-recommends-ocriplasmin-for-symptomatic-VMA_Final.pdf

Copyright © 2008 Eye Doc Talk. All rights reserved.